Search - tctmd.com

Displaying 1 - 20 of 32

Sort: Relevancy | Date

News Daily News

FDA: Class I Recall for Cook Medical’s CrossCath Support Catheters

L.A. McKeown

December 17, 2019

News Features

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

L.A. McKeown

December 12, 2019

News Conference News VEITH 2019

Endovascular Office-Based Labs: Balancing Upsides Against Potential for Abuse

L.A. McKeown

November 28, 2019

News Conference News VEITH 2019

Uproar Continues Over UK NICE Guidelines Restricting EVAR for AAA

L.A. McKeown

November 26, 2019

News Conference News VEITH 2019

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

L.A. McKeown

November 22, 2019

News Conference News VIVA 2019

Future Pulmonary Embolism Interventions: Wild West or Working Together?

L.A. McKeown

November 14, 2019

News Conference News VIVA 2019

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

L.A. McKeown

November 13, 2019

News Conference News VIVA 2019

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

L.A. McKeown

November 08, 2019

News Conference News VIVA 2019

Clinicians Get Real on Radiation: ‘Don’t Do Dumb Things’

L.A. McKeown

November 07, 2019

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Daily News

FDA: New Concerns Surface With Endologix Grafts for AAA

L.A. McKeown

October 28, 2019

News Daily News

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

L.A. McKeown

October 09, 2019

News Conference News TCT 2019

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

L.A. McKeown

September 28, 2019

News Conference News TCT 2019

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

L.A. McKeown

September 28, 2019

News Daily News

Microvascular Disease Quadruples Risk of Leg Amputation

L.A. McKeown

July 08, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News EuroPCR 2019

Small Study Lends Further Support to the Antiarrhythmic Potential of Renal Denervation

L.A. McKeown

June 06, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

Advertisement

FDA: Class I Recall for Cook Medical’s CrossCath Support Catheters

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

Endovascular Office-Based Labs: Balancing Upsides Against Potential for Abuse

Uproar Continues Over UK NICE Guidelines Restricting EVAR for AAA

More Real-world Data Support Safety of Paclitaxel-Based Devices in PAD

Future Pulmonary Embolism Interventions: Wild West or Working Together?

Calcium Conundrum: New Scores, Research Aim to Boost Outcomes in PAD Interventions

Nearly 1 Year Later, Endovascular Community Continues to Struggle With Paclitaxel

Clinicians Get Real on Radiation: ‘Don’t Do Dumb Things’

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

FDA: New Concerns Surface With Endologix Grafts for AAA

German Analysis Supports Long-term Safety of Paclitaxel-Based Therapies

LEVANT: Patient-Level Data Show No Increase in 5-Year Death for Paclitaxel DCBs in PAD

‘Spooky’ Signal Still Haunts Paclitaxel DCBs in PAD, but Updated Analysis Reassures

Microvascular Disease Quadruples Risk of Leg Amputation

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

Small Study Lends Further Support to the Antiarrhythmic Potential of Renal Denervation

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content